ClinicalTrials.gg

Program

NI-0101

Also written as “Cohort B: paridiprubart” and “SOC plus 15mg/kg EB05 IV”.

Its studies are mostly in Respiratory Distress Syndrome · COVID-19 · Arthritis, Rheumatoid, led by 3 companies.

Furthest: phase 3, since Nov 20, 20244 company-led studies, 2 open or runningNext primary completion: Jul 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PPD Development, LP22 open or runningphase 2since Nov 20, 2024Nov 20, 2024Jul 2028phase 2 · NCT06703073
Edesa Biotech10 open or runningphase 3since May 21, 2020May 21, 2020none ahead
Light Chain Bioscience - Novimmune10 open or runningphase 2since Jun 26, 2017Jun 26, 2017none ahead

Also a collaborator on its studies: jss-medical-research-inc, inflarx-gmbh and Hoffmann-La Roche.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 26, 2017First study: phase 2 study in Arthritis, RheumatoidNew to Light Chain Bioscience - NovimmuneLight Chain Bioscience - Novimmune · NCT03241108 · 90 enrolled · Bosnia and Herzegovina, Bulgaria, Georgia and more
  2. May 21, 2020Edesa Biotech's first study: phase 3 study in COVID-19New to Edesa BiotechEdesa Biotech · NCT04401475 · 278 enrolled · United States, Canada
  3. Nov 20, 2024PPD Development, LP's first studies: 2 phase 2 studies in Respiratory Distress SyndromeNew to PPD Development, LPPPD Development, LP · NCT06703073, NCT06701669

Ahead

  1. Jul 2028Primary completion: phase 2 study in Respiratory Distress SyndromePPD Development, LP · NCT06703073
  2. Jul 2028Primary completion: phase 2 study in Respiratory Distress SyndromePPD Development, LP · NCT06701669

TargetBeta

TLR4 →read by rule
“A monoclonal antibody directed against toll-like receptor 4 (TLR4), ”NCIt, by rule

Other programs on TLR4

ProgramCompanyFurthest phaseStudies
INI-2004ruleinimmune-corporationphase 22

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06703073Respiratory Distress Syndrome · United States2RecruitingPPD Development, LPJul 2028600
NCT06701669Respiratory Distress Syndrome · United States2RecruitingPPD Development, LPJul 2028200
NCT04401475COVID-19 · United States, Canada3TerminatedEdesa BiotechJul 22, 2024278
NCT03241108Arthritis, Rheumatoid · Bosnia and Herzegovina, Bulgaria, Georgia and more2CompletedLight Chain Bioscience - NovimmuneJun 20, 201890

How it is read

Names in the registry

  • “Cohort B: paridiprubart”, 2 entries
  • “SOC plus 15mg/kg EB05 IV”, 1 entry
  • “NI-0101”, 1 entry

Codes read as this program: EB05.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.